Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01934972 · ClinicalTrials.gov registry record · Phase 3
A Randomized Controlled Trial of Cognitive Remediation and D-cycloserine for Individuals With Bipolar Disorder
A Phase 3 study, sponsored by University of Arizona.
- Completed
- Registry status
- Phase 3
- Development phase
- 30
- Enrollment target
NCT01934972 is a Phase 3 study that has completed, run by University of Arizona. The registered enrollment target is 30 participants.
The verdict
NCT01934972, a Phase 3 study, has completed, sponsored by University of Arizona.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 30 participants
- Enrollment target
Study Summary
Individuals with bipolar suffer from problems in basic cognitive skills such as memory and concentration. Unfortunately, there are no current treatments that have been shown to improve cognitive skills among individuals with bipolar disorder. Computerized cognitive remediation (CR) is a treatment that has been shown to improve cognitive skills among individuals with serious mental illnesses other than bipolar disorder, such as schizophrenia. This treatment involves completing a series of activities on a computer that have been shown to improve cognitive skills. D-cycloserine (DCS) is an antibiotic traditionally used in the treatment of tuberculosis. Recent studies have suggested that this drug may also improve individuals' ability to learn. Thus, the goal of our study is to examine whether receipt of d-cycloserine increases the benefit that individuals receive from participation in cognitive remediation. To test this hypothesis, approximately forty subjects will be randomized to one of two study arms: \[i\] CR + DCS or \[ii\] CR + placebo. We will examine whether d-cycloserine increases the benefit that individuals with bipolar disorder receive from participation in cognitive remediation.
Interventions
- OTHER CR + DCS (D-cycloserine)
- OTHER CR + placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2013-03 |
| Est. Completion | 2017-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01934972
The ClinicalTrials.gov registry entry for NCT01934972 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arizona, which has 349 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which CR + DCS (D-cycloserine) is the first listed.
NCT01934972 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01934972 about?
NCT01934972 is a clinical study titled "A Randomized Controlled Trial of Cognitive Remediation and D-cycloserine for Individuals With Bipolar Disorder". Individuals with bipolar suffer from problems in basic cognitive skills such as memory and concentration. Unfortunately, there are no current treatments that have been shown to improve cognitive skills among individuals with bipolar disorder. Computerized cognitive remediation (CR) is a treatment t...
What is the current status of trial NCT01934972?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 30 participants. The study started on 2013-03. Estimated completion is 2017-04.
What interventions are being tested in trial NCT01934972?
The interventions under investigation include: CR + DCS (D-cycloserine) (OTHER), CR + placebo (OTHER).
Who is sponsoring clinical trial NCT01934972?
This trial is sponsored by University of Arizona, which has 349 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.